Clinical efficacy of Pidotimod adjuvant therapy on children with recurrent respiratory tract infection and its influence on immune function of children

Abstract

Objective To observe the therapeutic effect of pidotimods on children with recurrent respiratory infection, and its effect on immune function of children. Methods Forty-eight cases of recurrent respiratory tract infection children from June 2014 to June 2016 in the hospital were selected as the objects, the 48 cases were randomly divided into control group (anti-infection, relieving cough and resolving phlegm therapy) and experimental group (adjuvant use of pidotimod on the basis of the treatment in the control group), with 24 cases in each group. The time of symptom disappearance after treatment, the clinical effect after 6 months of follow-up and the changes of immunoglobulins (IgA, IgG, IgM) levels in the two groups before and after treatment were observed. Results Six months after treatment, the therapeutic effects and immune levels of the two groups were improved. The efficacy of the experimental group was significantly better than that of the control group (Z=-2.405, P 0.05). Comparison between the two groups, in the experimental group IgA, IgM were significantly higher than those in control group (t=3.607, 2.173, P 1.053). Conclusions Pidotimod can significantly improve the treatment efficacy on children with recurrent respiratory tract infection, reduce the incidence of infection, and can significantly increase and restore the immune globulin level, improve the immune function of children. So it has clinical value. Key words: Pidotimod; Immunoglobulin; Recurrent respiratory tract infection